HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Advances in the Clinical Management of Diabetic Macular Edema and Age-Related Macular Degeneration

Retina specialists explore the practical and clinical implications of the rapidly developing treatment spectrum for diabetic macular edema and age-related macular degeneration.

EP. 1: Prevalence and Public Awareness for DME and AMD

June 24th 2022

Carl D. Regillo, MD, FACS; Michael A. Klufas, MD; and David R. Lally, MD, discuss how increasing awareness regarding AMD and DME among patients and the medical community may lead to early treatment interventions.

EP. 2: Presentation and Diagnosis of DME and AMD

June 24th 2022

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, review the clinical benefits of early detection of AMD and DME.

EP. 3: Patient Communication and Shared Decision-Making in the Treatment of DME and AMD

July 1st 2022

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, share guidance on how to initiate conversations with patients who have been diagnosed with AMD or DME.

EP. 4: Therapeutic Selection and Standards of Care in DME and AMD

July 1st 2022

A panel of retina specialists discuss how to balance durability, visual acuity, and other factors when selecting the appropriate regimen for patients with AMD and DME.

EP. 5: Tailoring Treatment Regimens and Measuring Outcomes in DME and AMD

July 8th 2022

Dr Regillo, Dr Cooper, and Dr Klufas emphasize the importance of a personalized approach and share strategies for assessing outcomes in patients with AMD and DME.

EP. 6: The Role of Anti-VEGF Agents for DME and AMD

July 8th 2022

Dr Regillo leads a discussion with retina specialists about the utility and limitations of anti-VEGF agents in the treatment of patients with AMD and DME.

EP. 7: Considerations for Using Anti-VEGF Agents in AMD, DME

July 15th 2022

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the implications of real-world evidence indicating fewer visual gains associated with anti-VEGF therapies compared with clinical trials.

EP. 8: The Role of Faricimab in Treatment of AMD, DME

July 15th 2022

Carl D. Regillo, MD, FACS; and David R. Lally, MD, discuss the recent FDA approval of faricimab and the potential impact of having a molecule that inhibits 2 pathways that play a role in diabetic macular edema and neovascularization in the treatment armamentarium.

EP. 9: Reviewing Safety, Efficacy Data for Faricimab in AMD, DME

July 22nd 2022

Michael A. Klufas, MD, reviews the design and key findings from clinical trials for faricimab.

EP. 10: Considerations for the Use of a Novel Port Delivery System in the Treatment of Neovascular AMD

July 22nd 2022

Thought leaders review the clinical and practical implications of a novel port delivery system for the treatment of neovascular age-related macular degeneration [AMD].